Ibrutinib

🧮 Dose calculator

Chronic lymphocytic leukaemia (CLL) · Regimen source: FDA Imbruvica · 2.1

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Imbruvica · 2.1
• • Chronic GVHD: ≥12 years 420 mg; 1–<12 years 240 mg/m² (max 420). Swallow tablets or capsules whole with water. FDA Imbruvica · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Imbruvica · 8.1

  “Risk Summary IMBRUVICA can cause fetal harm based on findings from animal studies.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Imbruvica · 8.2

  “Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with IMBRUVICA and for 1 week after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Imbruvica · 8.4

  “Chronic GVHD The safety and effectiveness of IMBRUVICA have been established for treatment of cGVHD after failure of one or more lines of systemic therapy in pediatric patients 1 year of age and older.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Imbruvica · 8.5

  “No overall differences in effectiveness were observed between younger and older patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Imbruvica · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month after the last dose.”